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Purpose: Abdominal aortic aneurysm (AAA) is associated with chronic transmural inflammation and destruction of the
elastic media. The purpose of this study was to elucidate molecular mechanisms that might orchestrate leukocyte
recruitment into the outer aortic wall by determining whether CC chemokines contribute to development of aneurysm
degeneration in an elastase-induced mouse model of AAA.
Methods: Adult male C57BL/6J mice underwent transient elastase perfusion of the abdominal aorta to induce develop-
ment of AAA. At various intervals after elastase perfusion (0, 4, 7, 14 days), real-time reverse transcription polymerase
chain reaction and enzyme-linked immunosorbent assays were used to measure aortic wall expression of the CC ()
chemokines, monocyte chemoattractant protein-1 (MCP-1) and regulated on activation, normal T-cell expressed and
secreted (RANTES). Expression of these chemokines by cultured mouse aortic smooth muscle cells (AoSMC) was
similarly assessed after transient (5 minutes) exposure to elastase solutions in vitro.
Results: Mouse aortic diameter (mean  SEM) increased to aneurysmal proportions by 14 days after elastase perfusion
(from 0.51 0.03 mm to 1.34 0.32 mm; 163% increase; P < .05), with macrophage infiltration of the outer aortic wall
beginning within 7 to 10 days. Increased aortic wall messenger RNA expression for MCP-1 (28-fold) and RANTES
(11-fold) was observed on day 4, with maximal production of chemokine protein on day 7 (MCP-1, from 7.07  0.06
ng/mL to 19.60  0.19 ng/mL; P < .001; RANTES, from 0.23  0.006 ng/mL to 2.03  0.057 ng/mL; P < .001).
Neither MCP-1 nor RANTES was detected in normal mouse aorta with immunohistochemistry, but both chemokines
were abundant in AAA. Within 48 hours of transient exposure to elastase, cultured mouse AoSMC exhibited pronounced
induction (>90-fold) of MCP-1 and RANTES, despite concomitant decrease in cell numbers.
Conclusions: Increased mouse aortic wall expression of MCP-1 and RANTES occurs early in development of elastase-
induced AAA and before onset of the chronic inflammatory response. Moreover, elastase directly stimulates AoSMC
chemokine production in vitro. Elastase-induced medial SMC production of CC chemokines may therefore provide an
important link between enzymatic injury, leukocyte recruitment, and aneurysmal degeneration of the aortic wall. (J Vasc
Surg 2003;38:138-46.)
Human and experimental abdominal aortic aneurysms
(AAA) are characterized by a chronic transmural inflamma-
tory response composed of mononuclear phagocytes and
lymphocytes.1,2 Inflammatory cells infiltrating the outer
aortic wall are thought to be important in the destructive
connective tissue remodeling that occurs during aneurys-
mal degeneration, particularly through production of
proinflammatory cytokines and enzymes capable of degrad-
ing elastin, collagen, and other structurally important ma-
trix proteins.3-5 Recent investigations have helped define
the functional role of various matrix metalloproteinases
(MMP) in degenerative aneurysm disease, as well as the
potential use of MMP inhibitors in patients with small
asymptomatic AAA.6-8
Despite the recognized association between chronic
inflammation and aneurysm degeneration, specific factors
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responsible for leukocyte recruitment into the aortic media
remain unknown. This is of particular interest because of
recent evidence that the elastic media may represent an
“immune-privileged” site that exhibits restricted infiltra-
tion of monocytes, macrophages, and lymphocytes during
arterial wall inflammatory responses.9 It has been proposed
that matrix degradation might have a direct role in this
process, because biologically active peptides released by
enzymatic degradation of elastin stimulate monocyte che-
motaxis in vitro.10,11 In support of this hypothesis, it was
recently demonstrated that extracts of human AAA tissue
induce chemotactic responses in cultured monocytic cells
and that much of this response is attributable to ligand-
receptor interactions with the monocyte cell surface 67 kD
elastin binding protein.12
A similar molecular mechanism has been proposed to
explain development of experimental AAA in rats and mice
after transient perfusion of the aortic wall with porcine
pancreatic elastase, a commonly used model for investiga-
tion of aortic aneurysm.13-20 Under the appropriate exper-
imental conditions, this model is characterized by mild
aortic dilatation (50%) immediately after elastase perfu-
sion, with only limited structural injury to the aortic wall,
followed by development of a transmural inflammatory
response 7 to 14 days later. Delayed onset of the inflamma-
tory response is temporally and spatially associated with
elevated local expression of matrix-degrading proteinases,
progressive destruction of medial elastic fibers, and dilation
of the aortic wall to aneurysm proportions; furthermore,
inhibition of the inflammatory response effectively sup-
presses AAA development.17-20
While it appears plausible that transient exposure to
elastase might release a sufficiently high local concentration
of elastin degradation peptides (EDP) within the aortic wall
to initiate, sustain, and amplify a chronic inflammatory
response, it remains unknown whether generation of EDP
is the sole molecular mechanism operating in development
of elastase-induced AAA. In considering alternate mecha-
nisms, it is notable that several chemotactic cytokines with
activity for monocytes, macrophages, and lymphocytes are
produced in human AAA tissue, including the CXC che-
mokine interleukin-8 and the CC chemokines monocyte
chemoattractant protein-1 (MCP-1) and regulated on ac-
tivation, normal T-cell expressed and secreted (RAN-
TES).21,22 Given the varied and potent biologic activities
described for different members of the chemokine fami-
ly,23-27 we postulated that increased local expression of
these molecules might be an early event in the stepwise
progression of experimental aneurysm formation by pro-
moting leukocyte infiltration into the outer aortic wall. In
the present investigation we focused our interest on
MCP-1 and RANTES, because their roles in vascular biol-
ogy have been characterized to a greater extent than that of
other chemokines.
The purpose of this study was to investigate the poten-
tial role of CC chemokines in aneurysmal degeneration
with two experimental approaches: to examine whether
development of elastase-induced AAA in the mouse is
accompanied by altered local production of MCP-1 and
RANTES in vivo and to determine whether exposure of
cultured murine aortic smooth muscle cells (AoSMC) to
elastase has an effect on cellular chemokine expression. The
results of these experiments provide evidence that elastase-
induced production of CC chemokines within the aortic
media may be an important biologic mechanism underlying
experimental aneurysm degeneration.
MATERIALS AND METHODS
Experimental animals. C57BL/6 mice were pur-
chased from the Jackson Laboratory (Bangor, Me). All
experimental procedures were performed in male animals
that had reached maturity (8-10 weeks), according to a
protocol approved by the Animal Studies Committee at
Washington University School of Medicine.
Elastase perfusion model and aortic diameter mea-
surements. Mice (20-35 g) were anesthetized with intra-
peritoneal sodium pentobarbital (55-60 mg/kg), and lap-
arotomy was performed under sterile conditions as
described.20,28 The abdominal aorta was isolated with the
assistance of an operating stereomicroscope (Leica, Deer-
field, Ill), and the preperfusion aortic diameter was mea-
sured with a calibrated ocular grid. After placing temporary
ligatures around the proximal and distal aorta, an aorto-
tomy was created at the bifurcation with the tip of a
30-gauge needle. A heat-tapered segment of PE-10 poly-
ethylene tubing was introduced through the aortotomy
and secured, and the aortic lumen was perfused for 5
minutes at 100 mm Hg with normal saline solution con-
taining type I porcine pancreatic elastase (0.414 U/mL;
Sigma, St Louis, Mo). After removing the perfusion cath-
eter, the aortotomy was repaired without constriction of
the lumen, and the postperfusion aortic diameter was mea-
sured at least 5 minutes after restoration of flow to the
lower extremities. Animals were allowed free access to food
and water for various intervals up to 14 days, when the aorta
was reexposed at laparotomy under anesthesia. Final aortic
diameter measurements were obtained before euthanasia
and tissue procurement. Preperfusion, postperfusion, and
final aortic diameter measurements were recorded as mean
Å standard error (SE), and aortic diameter measurements at
each interval were compared with use of the paired Student
t test.29 For individual animals, AAA was defined as increase
in diameter (-aortic diameter) by at least 100% over
preperfusion diameter.20,28
Aortic explants. To examine aortic wall chemokine
expression in the absence of circulating cells or plasma
proteins, elastase-perfused abdominal aortic tissue was ob-
tained from three mice at each time examined (unperfused
day 0 and postperfusion days 1, 2, 4, 7, 14). The excised
segment of aorta was washed in cold phosphate-buffered
saline solution (PBS; Sigma), pH 7.4, then trimmed to 5
mm in length and divided further into four equal sections.
Each section was placed in a tissue culture well on a 96-well
plate (Corning, Corning, NY) and allowed to adhere for
approximately 5 minutes. Each well was filled with 200 L
of Dulbecco minimal essential medium (DMEM; BioWhit-
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taker; Walkersville, MD) supplemented with 1% lactalbu-
min hydrolysate, and the plates were incubated at 37°C for
12 hours in a humidified 5% CO2 atmosphere. The aortic
conditioned medium was then removed and centrifuged at
10,000g for 30 minutes.
Light microscopy and immunohistochemistry. The
abdominal aorta was excised after systemic perfusion-fixa-
tion with 10% neutral buffered formalin solution (120 mm
Hg for 10 minutes) and embedded in paraffin. Cross-
sections of aortic tissue (5 m) were stained with Verhoeff–
van Gieson for elastin and examined with light microscopy.
For immunohistochemistry, fresh aortic wall tissue was
excised, placed in Tissue-Tek OCT compound (Sakura
Finetek USA, Inc, Torrance, Calif), and snap-frozen in
liquid nitrogen. Frozen sections (10m) were immersed in
ice-cold acetone and treated with 0.3% hydrogen peroxide
for 5 minutes each, then rinsed with PBS and blocked for
15 minutes with 5% rabbit serum in PBS. Slides were
incubated with 2.5 g/mL of either rat anti-mouse RAN-
TES immunoglobulin G (IgG), rat anti-mouse MCP-1
IgG, or reagent grade nonimmune rat IgG (R&D Systems,
Minneapolis, Minn) overnight at 4°C in a humidified
chamber. Biotin-conjugated rabbit anti-rat IgG (1:200 in
PBS; Vector Laboratories, Burlingame, Calif) was applied
for 30 minutes at room temperature, followed by horserad-
ish peroxidase–conjugated avidin-biotin complex, and im-
mune complexes were detected with horseradish peroxi-
dase substrate (Vector Laboratories). Sections were
counterstained with hematoxylin before examination with
light microscopy.
Cultured mouse aortic smooth muscle cells. Seg-
ments of normal mouse aortic wall (1-2 mm2) were placed
in 96-well tissue culture plates containing DMEM supple-
mented with 10% fetal calf serum (FCS) and maintained at
37°C in a humidified 5% CO2 atmosphere. Tissue segments
were removed after sustained cellular outgrowth from the
explants was observed, and the remaining cells were al-
lowed to propagate to confluence. After dispersion with
0.25% trypsin and 0.5% ethylenediamine tetraacetic acid
(EDTA), an aliquot from each cellular isolate was charac-
terized by immunofluoresence with antibodies against
smooth muscle -actin, and the remaining cells were
pooled and replated in DMEM or 10% FCS. For specific
experiments, AoSMC in early passage (1 to 3) were dis-
persed, replated into 24-well plates at 50,000 cells per well,
and grown to confluence in DMEM or 10% FCS. Cells
were washed with PBS and exposed to varying concentra-
tions of elastase solution for 5 min at room temperature,
then washed with PBS and replenished with serum-free
medium (DMEM, 1% lactalbumin hydrolysate). The con-
ditioned medium (AoSMC-CM) was harvested 48 hours
after transient exposure to elastase for measurement of
chemokine proteins with an enzyme-linked immunosor-
bent assay (ELISA). The remaining adherent cells were
dispersed with trypsin or EDTA, and an aliquot was used to
determine AoSMC counts in triplicate with a hemocytom-
eter. The remaining AoSMC were used for isolation of total
cellular ribonucleic acid (RNA) with Trizol reagent, and
chemokine messenger RNA (mRNA) expression was mea-
sured with real-time reverse transcriptase polymerase chain
reaction (RT-PCR).
Quantitative (real-time) RT-PCR. To quantify lev-
els of chemokine mRNA expression within the intact aortic
wall, up to 4 pooled aortic tissue samples were obtained at
each experimental interval and pulverized under liquid
nitrogen. Total RNA was isolated with Trizol reagent
(Gibco BRL, Grand Island, NY).20,28 Each sample was
normalized to 1 g of total RNA, and complementary
deoxyribonucleic acid (cDNA) synthesis was performed in
a 50 L RT reaction on a GeneAmp 2400 thermal cycler
system with reagents provided by the manufacturer: 5.5
mmol/L of MgCl2, 0.5 mmol/L of deoxyribonucleoside
triphosphate, 1.25 U/L of MultiScribe Reverse Tran-
scriptase, and 2.5 mol/L of random hexamers (Applied
Biosystems, Foster City, Calif). The RT products served as
the template for real-time PCR analysis, with gene-specific
primers, reagents, and protocols provided in the SYBR
Green PCR kit and the GeneAmp 5700 Sequence Detec-
tion System (Applied Biosystems). All primers were se-
lected with PrimerExpress version 1.6 software (Applied
Biosystems), to amplify a 50 base pair (bp) product with a
temperature of 60°C and target sequences that flanked or
spanned an exon-exon junction in the murine mRNA tran-
script of interest. Primers used were mouse MCP-1 (Gen-
Bank Ref NM011333), forward primer (FP), GGC TCA
GCC AGA TGC AGT TAA (bp 154-174), reverse primer
(RP), GTG AAT GAG TAG CAG CAG GTG AGT (bp
181-204); mouse RANTES (GenBank Ref NM013653,
FP, GAG TAT TTC TAC ACC AGC AGC AAG TG (bp
184-209), RP, TGA CAA ACA CGA CTG CAA GAT TG
(bp 213-235); and mouse -actin, FP, CCC TAA GGC
CAA CCG TGA A (bp 255-273), RP, GTT GAA GGT
CTC AAA CAT GAT CTG (bp 306-283).
All real-time PCR reactions were performed in dupli-
cate with the following components (SYBR Green PCR
Core Reagents, Applied Biosystems): 10X SYBR PCR buff-
er; 3 mmol/L of magnesium chloride; 0.2 mmol/L of
deoxyadenosine triphosphate, deoxycytidine triphosphate,
and deoxyguanosine triphosphate; 0.4 mmol/L of de-
oxyuridine triphosphate; 25 mU/L of AmpliTaq Gold
DNA polymerase; 10 mU/L of AmpErase uracil DNA
glycosylase; 10 ng of cDNA or template standard DNA;
and 300 nmol/L each of the forward and reverse primers.
After initial incubation at 50°C (2 minutes) for AmpErase
activation and 95°C (10 minutes) for AmpliTaq Gold
activation, the samples underwent 40 cycles of PCR with
95°C for 15 seconds (melting) alternating with 60°C for 1
minute (anneal/extend). Direct detection of PCR products
was monitored by measuring increase in fluorescence
caused by binding of SYBR Green I to double-stranded
DNA products, along with an internal reference standard
(ROX). Fluorescence signals were analyzed with GeneAmp
5700 Sequence Detection System software version 1.3
(1999) according to the manufacturer’s recommendations
(Applied Biosystems). Real-time PCR reactions were per-
formed with serial dilutions of gene-specific DNA standard
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templates in parallel with the cDNA samples, to generate
standard curves for absolute quantitation of mRNA abun-
dance. At the conclusion of each PCR run, a dissociation
protocol was performed with the GeneAmp 5700 SDS
system, in which fluorescence is measured as a function of
temperature as the sample block is heated. A single peak of
the dissociation curve, generated with the SDS software,
was used to imply a single PCR product, and this was
confirmed in each case with gel electrophoresis
Results were recorded as semi-log plots of fluorescence
versus cycle number for melting curve analysis, and all
quantitative results were normalized to the mean concen-
tration of -actin to account for variability in quality and
amount of total RNA and efficiency of RT between sam-
ples. Relative change in gene expression was recorded as the
ratio of normalized target concentrations to -actin and
analyzed for statistical significance with the Student t test or
analysis of variance.29
Enzyme-linked immunosorbent assay. Aortic con-
ditioned medium or AoSMC-CM samples normalized to
total protein concentration were used to measure the con-
centration of mouse MCP-1 and RANTES secreted by
aortic explant cultures or cultured AoSMC, respectively.
Plates containing immobilized chemokine-specific anti-
bodies were obtained in commercially available ELISA kits,
and all assays were performed with reagents and instruc-
tions provided by the manufacturer (R&D Systems). Assays
for mouse MCP-1 were performed at 1:25 and 1:50 dilu-
tions, and assays for mouse RANTES were performed at
dilutions of 1:5 and 1:50. Results were expressed as mean
SEM and were compared with the Student t test or analysis
of variance.
RESULTS
Elastase-induced aneurysm degeneration. Consis-
tent with our previous studies with the elastase-induced
mouse model of AAA,20,28 aortic diameter increased to
aneurysm proportions between 7 and 14 days after elastase
perfusion, with mean ( SEM) aortic diameter increasing
from 0.51 0.03 mm before perfusion to 1.34 0.32 mm
on day 14 (P  .05). The overall extent of aortic dilation
was 163%  16% by day 14, with AAA developing in all
animals by this time. Light microscopy revealed minimal
structural damage to the aorta immediately after elastase
perfusion, followed by progressive infiltration of the outer
aortic wall by mononuclear phagocytes and lymphocytes
beginning within 7 to 10 days; the aortic wall inflammatory
response was accompanied by destruction of the elastic
lamellae, coinciding with the temporal onset of aneurysm
dilation.20,28
Aortic wall chemokine production. Although che-
mokine expression was negligible in the normal unperfused
aorta (day 0), expression of MCP-1 mRNA increased by
approximately 13-fold as early as 24 hours after elastase
perfusion (Fig 1). Aortic wall levels of MCP-1 mRNA were
increased further (up to 28-fold) by day 4, with sustained
elevation throughout the remainder of the 14-day experi-
ment. Aortic wall expression of RANTES mRNA was also
increased to a similar extent after elastase perfusion, with
maximal levels reached on day 4 being 11-fold greater than
those observed in normal aorta (Fig 1).
In determining whether increases in aortic wall chemo-
kine mRNA were reflected at the protein level, it was
necessary to consider that use of aortic wall homogenates
might be confounded by the presence of circulating cells
and plasma proteins. To minimize these potential sources
of chemokine protein, aortic wall samples were obtained at
various intervals after elastase perfusion and placed into
explant culture, and chemokine secretion into the fresh
conditioned medium was measured over 12 hours. Aortic
wall production of immunoreactive MCP-1 was slightly
decreased between baseline cultures (unperfused normal
aortas; day 0) and explants established up to 2 days after
elastase perfusion; however, MCP-1 secretion increased
rapidly after day 4, with maximal levels observed on day 7
(2.8-fold over normal aorta; P  .001) (Fig 2). Aortic wall
production of RANTES protein was also increased 4 days
after elastase perfusion, with maximal production observed
Fig 1. Mouse aortic wall expression of monocyte chemoattractant
protein–1 (MCP-1) and regulated on activation, normal T-cell
expressed and secreted (RANTES) mRNA after elastase perfusion.
Abdominal aortic wall specimens were harvested from three
C57BL/6 mice at each interval after transient (5 minutes) perfu-
sion with elastase, and chemokine mRNA expression was measured
with real-time reverse transcription polymerase chain reaction, as
described in the text. Data represent mean  SE of relative
transcript ratios measured for MCP-1 (A) and RANTES (B) as
normalized to -actin mRNA in the same specimens. *P  .05
compared with day 0.
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on day 7 (8.8-fold over normal aorta; P .001) (Fig 2). In
attempts to confirm this increase in aortic wall chemokine
production with immunohistochemistry, neither MCP-1
nor RANTES was detectable in normal aorta, but both
chemokines were abundant in aneurysm tissue between
days 7 and 14 (Fig 3). However, the high density of
infiltrating inflammatory cells made it difficult to discern
the specific aortic wall cell type or types responsible for
chemokine production.
Chemokine expression in AoSMC. Because the in-
crease in aortic wall expression of MCP-1 and RANTES
appeared to precede onset of elastase-induced aortic wall
inflammation by several days, it was postulated that tran-
sient exposure to elastase might directly influence chemo-
kine expression by vascular SMC that normally dominate
the aortic media. Indeed, vascular SMC would be in an
optimal position to stimulate leukocyte infiltration into the
elastic media, where degradation of elastin is thought to be
a crucial step in aneurysm formation. To test this hypothe-
sis, confluent cultures of mouse AoSMC were briefly ex-
posed to elastase solutions in vitro, and chemokine produc-
tion was measured over the next 48 hours. Negligible
amounts of MCP-1 and RANTES were produced by
AoSMC under basal culture conditions or after exposure to
saline solution alone; however, there was substantial in-
Fig 2. Mouse aortic wall secretion of monocyte chemoattractant
protein–1 (MCP-1) and regulated on activation, normal T-cell
expressed and secreted (RANTES) after elastase perfusion. Ab-
dominal aortic wall specimens were harvested from three
C57BL/6 mice at each interval after transient (5 minutes) perfu-
sion with elastase and placed in explant culture. Chemokine secre-
tion into the 48-hour conditioned medium was measured with
ELISA. Data represent mean  SE of immunoreactive protein
measured for MCP-1 (A) and RANTES (B). *P  .05 compared
with day 0.
Fig 3. Immunolocalization of chemokine proteins in mouse aortic
aneurysm. Representative transverse sections of mouse aortic tissue
obtained before and after transient perfusion with elastase. Sec-
tions shown were stained for regulated on activation, normal T-cell
expressed and secreted (RANTES) with immunoperoxidase tech-
niques, as described in the text. RANTES protein was undetectable
in normal unperfused aorta (A), but was abundant in elastase-
injured tissues on day 7 (B), where it appeared localized to medial
SMC (arrows), and on day 14 (C), where it appeared localized to
mononuclear phagocytes infiltrating the aortic media (arrows).
The same patterns were observed after staining aortic tissues for
monocyte chemoattractant protein–1 (not shown). Sections are
oriented with the vessel lumen at the top and the adventitia at the
bottom (original magnification, 100	).
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crease in both of these proteins after transient (5 minutes)
exposure to elastase (Fig 4). This response depended on the
concentration of elastase used, and was maximal at the same
elastase concentration normally used during aortic perfu-
sion to induce development of AAA in vivo, reaching a
98-fold increase in MCP-1 production and a 93-fold in-
crease in RANTES (both P  .05 compared with AoSMC
exposed to saline solution alone). These elastase-induced
changes in chemokine protein were reflected by similar
increases in AoSMC expression of chemokine mRNA as
measured with RT-PCR (data not shown). The observed
increases in chemokine production are especially striking
because exposure to elastase also caused a decrease in
AoSMC number over the same period, consistent with
toxicity or induction of cell death (Table).
DISCUSSION
Elastase-induced aortic aneurysm provides a useful ex-
perimental model with which to investigate the molecular
and cellular events underlying aneurysm degeneration. Al-
though this mouse model recapitulates a number of impor-
tant features of AAA in human beings, many specific mech-
anisms underlying development of elastase-induced AAA
are unresolved. The present investigation was designed to
examine the hypothesis that increased local expression of
CC chemokines might be one factor serving to orchestrate
leukocyte recruitment into the outer aortic wall during
development of experimental AAA, with the major findings
that elastase-induced aneurysm degeneration is accompa-
nied by early and pronounced increase in aortic wall expres-
sion of MCP-1 and RANTES, at both mRNA and protein
levels; increase in chemokine production precedes onset of
aortic wall infiltration by mononuclear phagocytes and
lymphocytes; and transient in vitro exposure to elastase
solutions is sufficient to induce rapid and sustained expres-
sion of MCP-1 and RANTES in cultured AoSMC. The
demonstration that increased CC chemokine expression
accompanies elastase-induced injury in vivo and that ele-
vated expression of CC chemokines is an early SMC re-
sponse to elastase-induced injury indicates that MCP-1 and
RANTES likely contribute to development and amplifica-
tion of aortic wall inflammation that characterizes experi-
mental aortic aneurysms.
Chemokines are a superfamily of small secreted pro-
teins (8-16 kD) characterized by specific motifs in their
N-terminal amino acid sequences.23-27 They are classified
into four subgroups on the basis of patterns exhibited by
the first two cysteine (C) residues: CXC () chemokines,
CC () chemokines, C (
) chemokines, and CX3C ()
chemokines. These chemotactic cytokines exert their bio-
logic effects by interacting with specific G protein–coupled
(seven transmembrane) cellular receptors, which are also
classified into subgroups according to their ligand binding
affinities: CXCR1 through CXCR5 receptors bind CXC
chemokines; CCR1 through CCR9 receptors bind CC
chemokines; XCR1 receptor binds the C chemokine lym-
photactin; and the CX3CR1 receptor binds the -chemo-
kine fractaline.
MCP-1 and RANTES are representative of the CC
chemokine subfamily, and they exert an important spec-
trum of effects in inflammation and immune respons-
es.23-27 MCP-1 can be produced by virtually all cell types
present in the arterial wall, including vascular endothelium,
smooth muscle, and monocyte-derived macrophages, and
its expression is rapidly induced by cytokines (eg, tumor
necrosis factor- and interleukin-1), lipopolysaccharide,
and other proinflammatory stimuli. MCP-1 exerts chemo-
tactic activity most prominently for monocytes, but it may
also stimulate T lymphocytes, natural killer cells, basophils,
dendritic cells, and vascular SMC.23-27 The specific inter-
action that mediates these responses appears to be binding
of MCP-1 and its relatives (MCP-2, MCP-3, MCP-4) to
the CCR2 receptor. MCP-1 is expressed in the arterial wall
Fig 4. Mouse aortic smooth muscle cell (AoSMC) chemokine
production after exposure to elastase. Cultured mouse AoSMC
were exposed to saline solution containing various concentrations
of elastase for 5 minutes and washed with PBS, and chemokine
secretion into the conditioned medium over the next 48 hours was
measured with ELISA. Data represent mean Å SE of immunore-
active protein measured for monocyte chemoattractant protein–1
(MCP-1) (A) and regulated on activation, normal T-cell expressed
and secreted (RANTES) (B). Concentrations of elastase used in
these experiments were based on the standard elastase concentra-
tion used for induction of experimental AAA in vivo (1	 0.414
U/mL of type I porcine pancreatic elastase (Sigma, St Louis, Mo).
*P  .05 compared with saline solution alone.
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during atherogenesis, and after balloon angioplasty in hu-
man beings and experimental models30-36 it is expressed by
vascular SMC and mononuclear phagocytes in atheroscle-
rotic lesions30,33,35 and is increased in the circulation of
patients with acute myocardial infarction,37 congestive
heart failure,38 and recurrent stenosis after coronary angio-
plasty.39 Experimental studies in animals deficient in
MCP-1 (or its CCR2 receptor), or with use of MCP-1
blocking antibodies, have consistently demonstrated re-
duction in atherosclerosis and intimal hyperplasia.34,40-43
Although most responses evoked by MCP-1 appear to
favor destruction of extracellular matrix through release of
various proteinases by activated inflammatory cells, it is
interesting that MCP-1 may have additional effects that
counter extracellular matrix degradation in inflammatory
diseases, because it can induce fibroblast collagen synthesis
and tissue fibrosis, and induce interstitial collagenase ex-
pression.44,45
RANTES is produced by T lymphocytes, endothelial
cells, and platelets. While RANTES acts on many of the
same cell types as MCP-1, it also has especially prominent
chemotactic activity for eosinophils, which may reflect an
important role in allergic inflammation, ie, asthma. RAN-
TES is also expressed in atherosclerotic carotid artery
plaques and in the accelerated coronary atherosclerosis
associated with heart transplantation.46,47 In contrast to
the restricted interaction between MCP-1 and its CCR2
receptor, chemotactic activity of RANTES is associated
with binding to CCR1, CCR3, and CCR5.
As in previous studies from this laboratory, we found
that transient elastase perfusion consistently results in de-
velopment of aortic aneurysm, with maximal dilatation
occurring between 7 and 14 days.20,28 Based on measure-
ment of protein concentration in the conditioned medium
obtained from short-term aortic explants harvested at var-
ious intervals, we found that increased production of both
MCP-1 and RANTES occurred early after elastase perfu-
sion and reached maximal levels by postperfusion day 7.
This temporal pattern of increased chemokine protein pro-
duction is closely correlated with the time course of mono-
nuclear cell infiltration into the aortic media, typically ob-
served to begin between postperfusion days 7 and 14 in this
model.
Inasmuch as mononuclear phagocytes and lympho-
cytes both produce and respond to MCP-1 and RANTES,
one concern in interpreting these findings is that increased
chemokine production between days 7 and 14 may simply
reflect the increased number of inflammatory cells within
the aortic media at these later intervals. Thus, to help
differentiate between an increase in aortic wall cell number
versus an actual increase in cellular chemokine expression,
quantitative (real time) RT-PCR techniques were used to
measure expression of MCP-1 and RANTES mRNA at
various intervals during development of elastase-induced
AAA. These experiments clearly demonstrate a pronounced
increase in chemokine mRNA production as early as post-
perfusion day 4; because the RT-PCR assays were standard-
ized to -actin to account for cell number, these results also
confirm that chemokine mRNA expression is upregulated
before the peak in total chemokine production, as mea-
sured with immunoassays. Aortic wall chemokine produc-
tion thereby is most likely induced at the transcriptional
level before development of the mononuclear inflammatory
response, implying a role for these proteins in orchestrating
the initial stages of leukocyte recruitment. Moreover, sus-
tained chemokine expression at later intervals is most likely
due to expression by mononuclear phagocytes and lympho-
cytes infiltrating the aortic wall, and it may serve to further
amplify and sustain the inflammatory process while the
aneurysm is rapidly expanding.
Previous interpretations of the elastase-induced model
of AAA have focused on the notion that local generation of
biologically active EDP likely is critical in initiating mono-
nuclear inflammation and the subsequent events responsi-
ble for aneurysm degeneration. It is also possible that
peptides generated by elastase-mediated matrix degrada-
tion might act to induce expression of MCP-1, RANTES,
and other chemokines by resident aortic wall cell types, eg,
medial SMC, before development of inflammatory cell
recruitment. However, our in vitro studies make it evident
that transient exposure to elastase solutions specifically and
directly induces rapid increase in vascular SMC expression
of both MCP-1 and RANTES, despite the observation that
elastase also causes vascular SMC death. Indeed, it is pos-
sible that elastase-induced vascular SMC toxicity and che-
mokine production are linked in vivo as well and that
increased chemokine production during evolution of an
aneurysm may reflect changes accompanying elastase-in-
duced death of medial SMC. Further studies are therefore
needed to examine the possible relationships between ela-
stase-induced SMC death, elevated local expression of che-
mokines, and progression of aneurysm degeneration.
Effects of elastase on AoSMC proliferation in vitro
Treatment Baseline 48 hours % decrease P
Saline solution 157,400  13,155 146,440  7600 7 NS
Elastase 0.1X 194,920  39,924 150,333  10,276 23 NS
Elastase 1X 172,947  34,445 82,733  4759 52 NS
Elastase 10X 160,587  13,438 39,133  5056 76 .05
AoSMC, Aortic smooth muscle cell; NS, not significant.
AoSMC counts were obtained in triplicate at baseline at 48 hours after transient (5 minutes) exposure to various concentrations of elastase solution.
Differences in cell number at 48 hours were compared with the student t test.
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Although the mechanisms responsible for the elastase-
induced increase in chemokine expression remain un-
known, the rapid and large increase in medial SMC chemo-
kine production may be especially important in initiating
leukocyte recruitment into the elastase-injured aortic wall.
Nonetheless, it is not yet known whether either MCP-1 or
RANTES is pivotal in elastase-induced aneurysm develop-
ment or simply part of several complementary molecular
pathways that might promote leukocyte recruitment dur-
ing this process. Further investigations will therefore be
necessary, including use of mice with targeted deletions of
MCP-1, RANTES, or their cellular receptors, to more
accurately determine the functional contributions these
proteins might make to experimental aneurysm formation.
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